Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer

被引：0
|
作者：
Colette A. Whitney
Lauren E. Howard
Stephen J. Freedland
Amanda M. DeHoedt
Christopher L. Amling
William J. Aronson
Matthew R. Cooperberg
Christopher J. Kane
Martha K. Terris
Timothy J. Daskivich
机构：
[1] Durham Veterans Affairs Medical Center,Division of Urology
[2] Duke University School of Medicine,Department of Biostatistics and Bioinformatics
[3] Cedars-Sinai Medical Center,Division of Urology
[4] Oregon Health Sciences University,Department of Urology
[5] West Los Angeles Veterans Affairs Medical Center,Division of Urology
[6] University of California,Department of Urology
[7] University of California,Department of Urology
[8] Charlie Norwood Veterans Affairs Medical Center,Division of Urology
[9] Medical College of Georgia,Division of Urology
来源：
Prostate Cancer and Prostatic Diseases | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：252 / 260
页数：8
相关论文
共 50 条
  • [1] Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
    Whitney, Colette A.
    Howard, Lauren E.
    Freedland, Stephen J.
    DeHoedt, Amanda M.
    Amling, Christopher L.
    Aronson, William J.
    Cooperberg, Matthew R.
    Kane, Christopher J.
    Terris, Martha K.
    Daskivich, Timothy J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (02) : 252 - 260
  • [2] IMPACT OF AGE, COMORBIDITY, AND PSA DOUBLING TIME ON LONG-TERM COMPETING RISKS FOR MORTALITY AMONG MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Whitney, Colette
    Howard, Lauren
    Freedland, Stephen
    Amling, Christopher
    Aronson, William
    Cooperberg, Matthew
    Kane, Christopher
    Terris, Martha
    Daskivich, Timothy
    JOURNAL OF UROLOGY, 2017, 197 (04): : E59 - E60
  • [3] Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer
    Howard, Lauren E.
    Moreira, Daniel M.
    De Hoedt, Amanda
    Aronson, William J.
    Kane, Christopher J.
    Amling, Christopher L.
    Cooperberg, Matthew R.
    Terris, Martha K.
    Freedland, Stephen J.
    BJU INTERNATIONAL, 2017, 120 (5B) : E80 - E86
  • [4] PREDICTORS OF TIME TO METASTASIS IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Moreira, Daniel
    Howard, Lauren
    Sourbeer, Katie
    Kundich, Robert
    Kane, Christopher
    Aronson, William
    Terris, Martha
    Cooperberg, Matthew
    Amling, Christopher
    Freedland, Stephen
    JOURNAL OF UROLOGY, 2014, 191 (04): : E921 - E921
  • [5] Darolutamide for non-metastatic, castration-resistant prostate cancer
    Burki, Talha
    LANCET ONCOLOGY, 2019, 20 (03): : E139 - E139
  • [6] Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients.
    Freedland, Stephen J.
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Huang, Ahong
    Wang, Li
    Baser, Onur
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer
    Rihito Aizawa
    Kenji Takayama
    Kiyonao Nakamura
    Takahiro Inoue
    Takashi Kobayashi
    Shusuke Akamatsu
    Toshinari Yamasaki
    Osamu Ogawa
    Takashi Mizowaki
    International Journal of Clinical Oncology, 2018, 23 : 749 - 756
  • [8] Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer
    Aizawa, Rihito
    Takayama, Kenji
    Nakamura, Kiyonao
    Inoue, Takahiro
    Kobayashi, Takashi
    Akamatsu, Shusuke
    Yamasaki, Toshinari
    Ogawa, Osamu
    Mizowaki, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (04) : 749 - 756
  • [9] Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months - a post-hoc analysis of a randomised trial
    Wong, S.
    Miller, K.
    Smith, M. R.
    Dearnaley, D.
    Dogliott, L.
    Egerdie, B.
    Fizazi, K.
    Kueppers, F.
    Montes De Oca, L.
    Morote, J.
    Pavlik, I.
    Sieber, P.
    Tammel, T. J.
    Van Poppel, H.
    Wirth, M.
    Ye, Z.
    Braun, A.
    BJU INTERNATIONAL, 2013, 111 : 37 - 38
  • [10] Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists
    Bonde, Tiago M.
    Westerberg, Marcus
    Aly, Markus
    Eklund, Martin
    Adolfsson, Jan
    Bill-Axelson, Anna
    Garmo, Hans
    Stattin, Par
    Robinson, David
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (03) : 169 - 175
12345